---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-003950"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-28T00:09:46.024148+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics appoints Dr. Rajiv Patni to Board of Directors

## Summary
- Board increased from seven to eight directors on January 15, 2025.
- Dr. Patni appointed as Class II director, term expiring at 2026 annual meeting.
- He brings experience as CEO of Judo Bio and former CRO at Reata Pharmaceuticals.
- Granted option to purchase 44,000 shares at $0.3465, vesting over three years.
- Eligible for standard non-employee director compensation program.

## SEC filing metadata
- accession: 0001104659-25-003950
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925003950/0001104659-25-003950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925003950/tm253320d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-003950
- JSON: https://secwatch.observer/filing/0001104659-25-003950.json
- Plain text: https://secwatch.observer/filing/0001104659-25-003950.txt

## Key facts
- Executive change
  Dr. Rajiv Patni was appointed as Director at BioXcel Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 15, 2025, the Board appointed Dr. Rajiv Patni to the Board, effective January 15, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465925003950/0001104659-25-003950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.